The Kava Anxiety Depression Spectrum Study (KADSS): A Randomized, Placebo-Controlled Crossover Trial Using An Aqueous Extract Of Piper Methysticum

Publication Type:
Journal Article
Psychopharmacology, 2009, 205 (3), pp. 399 - 407
Issue Date:
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2010003354OK.pdf210.03 kB
Adobe PDF
Rationale Piper methysticum (Kava) has been withdrawn in European, British, and Canadian markets due to concerns over hepatotoxic reactions. The WHO recently recommended research into aqueous extracts of Kava. Objective The objective of this study was to
Please use this identifier to cite or link to this item: